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Postpartum haemorrhage (PPH) is the leading cause of death in pregnancy globally, causing 187 deaths daily (1). In many more it leads to anaemia, blood transfusion, surgery and psychological morbidity. This burden of disease makes it a global priority to improve PPH management. Critical to this is the need to agree a simple fact: what exactly is a PPH? 

Official Definitions
During a WHO ‘informal meeting of experts’ in 1989, PPH was defined as ‘the loss of 500mls or more of blood from the genital tract after delivery of the baby’ (2). This definition has been widely cited, and relatively unchallenged until recently, despite the meeting’s report acknowledging 500ml as ‘an arbitrary figure’ and ‘not always of great clinical significance’. 

In recent years professional societies have developed definitions with more clinical significance. The Royal College of Obstetricians and Gynaecologists (RCOG) in 2011 endorsed the 500ml threshold in their definition of ‘Minor PPH’, although stated that 1000ml (or a lesser volume with clinical shock), should be classed as ‘Major PPH.’ They recommend ‘readiness for resuscitation’ in response to blood loss 500-1000ml, but ‘a full protocol of measures’ when the blood loss reaches 1000ml or clinical signs of shock (3). The American College of Obstetricians and Gynaecologists (ACOG) held a modified Delphi vote of its members in 2014 to reach a consensus on a PPH definition. They dismissed the 500ml cut-off, endorsing a definition of ‘greater or equal to 1000ml or blood loss with signs or symptoms of hypovolaemia.’ (4) The WHO avoided a specific recommendation in their 2012 guidelines, instead commenting that “PPH is commonly defined as blood loss 500ml or more (5).” The most recent WHO-endorsed definition was instead for ‘Severe PPH’, defined by the WHO Working Group on Maternal Mortality and Morbidity Classifications as ‘genital bleeding after delivery, with at least one of the following: perceived abnormal bleeding (1000 ml or more) or any bleeding with hypotension or blood transfusion’ (6).

Definitions based on the volume of blood loss
A review of primary outcomes used in PPH prevention randomized controlled trials (RCTs) and Systematic Reviews (SRs) reported that ≥500ml was the most common primary outcome in RCTs (24/82), whereas ≥1000ml was preferred in SRs (10/77) (7). The preference for 500ml in trials but 1000ml in systematic reviews most likely reflects trialists’ desire to maximize statistical power versus reviewers’ preference for outcomes more closely associated with morbidity.

But definitions based on blood loss volume all suffer from the inaccuracies inherent in blood loss quantification - practitioners underestimate by 46-75% with greater errors at higher losses (8). This is one argument for choosing a 500ml threshold: it reduces the number of unidentified cases with more than 1000ml of blood loss by sacrificing specificity for a higher sensitivity. Diagnostic accuracy can be improved by direct measurement of blood in under-buttock calibrated drapes. Unfortunately, as routine use of calibrated drapes has not been associated with a decrease in severe PPH, their use at every delivery is hard to justify outside of research (9). Many clinicians compromise by using collection drapes for high-risk deliveries, and retrospectively weighing blood-soaked materials after PPH at other deliveries.

In selecting a blood loss threshold, we are attempting to find a division between normal bleeding and abnormal bleeding. But what is normal bleeding? In 9348 low-risk vaginal deliveries with no third stage prophylaxis and no treatment until 700ml of blood loss, the mean, mode and median of measured blood loss were between 200 and 300ml (10). However, what is the upper limit of normal: the 75th centile - 310ml; the 90th - 720ml; or the 95th centile - 900ml? The choice is arbitrary, with the resulting definition somewhat illogically excluding those at highest risk of PPH. Indeed, the normal blood loss of any population varies hugely depending on the environment (e.g. altitude), ethnicity, the pregnancy itself (e.g. multiple pregnancy), and health care factors (including obstetric interventions and PPH prophylaxis) (3). 

Importantly, an individual’s tolerance of blood loss will also widely vary. The presence of anaemia, endemic in many regions due to malaria, dietary deficiencies and intestinal worms, will be critical in determining the consequences of blood loss. Routine calculation of the blood loss as a percentage of total blood volume (using weight and height) would take account of the woman’s habitus, but the challenges of blood measurement persist. 

Definitions based on physiological changes
An alternative approach is to define PPH by a fall in haematocrit by >10% or haemoglobin concentration (>2g/dl) on blood samples taken before and after delivery. While this has many advantages, it is markedly affected by intravascular fluid depletion (with pre-eclampsia or dehydration), infusions of fluid or blood, and the physiological postpartum rise. Furthermore, it requires laboratory facilities and only permits a delayed diagnosis. 

Vital signs have been used by some authors and professional societies in their definitions to capture the effects of bleeding. Their measurement has the advantage of being standard management already, relatively easy, cheap and objective. A systematic review into the relationship between blood loss and clinical signs highlighted that shock index (heart rate divided by systolic blood pressure) was the most promising clinical sign for this purpose (11). However, shock index alone has a low specificity for PPH, and there is insufficient evidence at present to recommend a cut-off to be used as part of a PPH definition.

Definitions based on need for intervention
Interventions for PPH, for example the need for additional uterotonics, are a pragmatic way to define PPH. However practitioners tend to commence treatment early in the bleeding, for example in response to a rapid rate of bleeding (8). Indeed, a secondary analysis of four large randomized trials found little correlation between additional uterotonic medication and final measured blood loss, with two trials finding the majority of women receiving uterotonics had a final blood loss of less than 500ml (7). Identifying cases retrospectively can also present a challenge, as it may be unclear if medication was given as prophylaxis or treatment. 

The aforementioned approaches are all unsatisfactory as they fail to measure what is most important to the woman - adverse outcomes. Postpartum bleeding may cause a new mother to be light-headed, weak and unable to feed her baby. But she may also develop organ dysfunction, require blood products, surgery, be admitted to intensive care, or even die as a result of PPH. Adverse clinical outcomes like these should be central when developing a consensus on PPH definition so that it accurately captures the morbidity caused by the disease. 

The need for different definitions
It is important to separate out the level of bleeding at which treatment is initiated, and that at which PPH, as an adverse outcome, is defined. Although previous definitions have tried to hold both together, a value of 500mls satisfies neither requirement. No clinician would sit back and watch a rapid atonic or traumatic PPH, waiting for it to reach an arbitrary value before initiating treatment. 

Consider the analogy of a town with a flood-prone river running through it. In heavy rainfall, shopkeepers are likely to lay sandbags across the front of their shops as soon as they see the water level rapidly rising. The official definition of ‘flooding’ may be that the river spills over the quay – but that doesn’t represent the point at which action should be taken. Nor does it adequately quantify the flood damage. It makes more sense to have two measures. One is an early measure based on underlying risk, vulnerability and rate of change, which indicates the point at which evasive action should be taken in order to prevent harm. The second quantifies the actual harm caused.

Creating different definitions for different purposes
1. To decide when to start treatment. 
Early treatment, when bleeding is first recognized to be abnormal, has relatively few risks and could stop bleeding progressing to coagulopathy. Proactive treatment to prevent adverse outcomes in these patients is entirely logical and should be supported. Therefore, we would suggest that initial measures are started as soon as the bleeding is noted to be abnormal or, failing that, causes symptoms or signs. 

2. A definition for audit purposes
Repeated studies show that estimated blood loss is too inaccurate and unreliable to be used as a measure of quality of care. Audits of treatment do allow insights into clinical practice (informing training and quality improvement), but they have limited value in monitoring PPH morbidity. Measurement of PPH-related adverse outcomes should instead be prioritized, accepting that in many cases they will require the use of proxy outcomes such as transfusion or hysterectomy, which have their own problems of inconsistency. 

3. A definition for use in research
The very poor specificity of a 500ml cut-off for maternal morbidity makes it virtually useless as a clinical research outcome. It only retains its popularity through researchers looking for frequently occurring adverse outcomes to give statistical power to small clinical trials. But the use of a 500ml cut-off in this situation may be misleading, or even dangerous. A PPH treatment that shows benefit at 500mls may have no benefit at all for important larger bleeds (e.g. due to abruption, or placenta praevia) and may thereby be recommended unjustifiably, wasting resources and time. Conversely, a negative study powered to detect changes at 500mls may miss an important effect on major haemorrhage. It is critical, therefore, that clinical studies are powered (and funded) to detect changes in maternal morbidity, not just an arbitrary blood loss cut-offs, especially of 500mls.

A suitable morbidity outcome might be the WHO maternal near-miss criteria (12) using the features relevant to PPH (shock, transfusion of over 5 units, hysterectomy, coagulopathy or oliguria). Those needing a blood loss cut-off should use a minimum of 1000mls, reflecting a level with a closer correlation with maternal morbidity. This is supported by consensus-building work already completed by ACOG and WHO as well as the ongoing work on core outcome sets by COMET.  Our international working group reached a consensus on this approach for a definition of PPH for research (13). A large cohort study could identify the best proxy outcome for a PPH adverse event, by providing the sensitivity and specificity of numerous measures (e.g. 500ml, 1000ml, units of blood transfused, shock index). A proxy outcome may allow interventions to be compared without the need for huge sample sizes, though it will never replace the value of an adverse event as an outcome in itself. 
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